Personalized patient support to guide your patients through treatment with ONPATTRO® (patisiran)
Additional questions? Call 1-833-256-2748
Alnylam Assist® can help with:
Coverage for ONPATTRO will vary by plan and by patient. Alnylam Assist® can help determine patient-specific coverage requirements.
Alnylam Field Reimbursement Directors (FRDs) can provide education about ONPATTRO billing and coding, chart documentation, payer requirements and processes for prior authorizations, claims, and appeals.
Disease & product education
Alnylam Patient Education Liaisons (PELs) are available to provide education to patients about the disease and treatment with ONPATTRO.
PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice.
The Alnylam Assist® team will provide you with information about how to order ONPATTRO.
Eligible patientsa may qualify for the Patient Assistance Program (PAP) or Commercial Copay Program.
Important Safety Information and Indication
Important Safety Information
Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.
To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.
Reduced Serum Vitamin A Levels and Recommended Supplementation
ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).
The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).
ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
For additional information about ONPATTRO, please see the full Prescribing Information.